Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment
The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in \[14C\] AC0010 ADME.
Carcinomaï¼ŒNon-Small-Cell Lung
DRUG: AC0010
Objective Response Rate, To assess the overall Objective Response Rate(ORR) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC., RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months
Progression Free Survival, To assess the Progression Free Survival(PFS) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC., RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months|Disease control rate, To assess the Disease control rate(DCR) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC., RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months|Number of adverse events (AE) experienced by patients to assess safety, To assess the safety of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC., From date of Signed informed consent forms until 30 days after disease progression, intolerable toxicity or withdrawal from study, approximately up to 18 months)
The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in \[14C\] AC0010 ADME (absorption, distribution, metabolism and excretion) trial and subsequent receiving AC0010 treatment.